Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Feb;13(2):e70072.
doi: 10.1002/mgg3.70072.

Novel De Novo RALA Missense Variants Expand the Genotype Spectrum of Hiatt-Neu-Cooper Neurodevelopmental Syndrome

Affiliations
Case Reports

Novel De Novo RALA Missense Variants Expand the Genotype Spectrum of Hiatt-Neu-Cooper Neurodevelopmental Syndrome

Alice Dainelli et al. Mol Genet Genomic Med. 2025 Feb.

Abstract

Background: RALA is a small GTPase from the RAS superfamily implicated in signal transduction and cytoskeletal dynamics. Recently, de novo variants in RALA have been associated with a neurodevelopmental syndrome characterized by intellectual disability (ID), developmental delay (DD), and seizures. So far, only < 12 patients have been reported.

Methods: In this study, we report two novel patients with neurodevelopmental impairment and epilepsy carrying previously unreported RALA variants. We performed a thorough clinical investigation of these patients and performed brain MRI to detect potential abnormalities. Trio-exome sequencing and/or NGS panel testing were conducted to identify the genetic variants. Then, we reviewed previous cases reported in the literature.

Results: Affected individuals showed a complex neurodevelopmental phenotype consistent with Hiatt-Neu-Cooper neurodevelopmental syndrome. Brain MRI in both subjects showed abnormalities including megalencephaly and ventricular enlargement, previously unreported in RALA patients. Genetic testing revealed two novel de novo missense variants in RALA: c.217G>A, p.(Glu73Lys) in case #1 and c.73G>C, p.(Val25Leu) in case #2. Both variants affect highly conserved residues within the GTP/GDP-binding site of the protein. These changes are predicted to be deleterious by in silico tools, interfering with the GTPase activity of RALA.

Conclusion: Our findings expand the genotype and phenotype spectrum of Hiatt-Neu-Cooper neurodevelopmental syndrome. Our observations also support the important role of variants affecting the GTP/GDP-binding site of the RALA protein in the pathogenesis of Hiatt-Neu-Cooper neurodevelopmental syndrome.

Keywords: GTPase; RALA; brain abnormalities; epilepsy; exome sequencing; intellectual disability; neurodevelopmental syndrome.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Clinical and genetic findings. (A) Frontal and lateral view of the facial features of patient 1, showing broad forehead, triangular face, down‐slanting palpebral fissures, exotropia, mandibular hypoplasia with pointed chin, and low‐set ears. (B) Patient 2 showing dysmorphic features: Mild epicanthus, short nose with flattened nasal bridge, slightly anteverted nares, and mandibular hypoplasia with pointed chin. (C) EEG showing disorganized posterior rhythm with superimposed slow anterior activity and high‐voltage bilateral spikes, polispikes, and sharp waves, predominantly over the temporal and central regions, enhanced during sleep. (D) Linear structure of the RALA protein, showing the GTP/GDP‐binding regions (GBR), effector region (ER), effector domain (ED), and post‐translational modification regions (PTM). The GBR is essential for the protein's molecular switch activity, while the ER and ED mediate interactions with downstream effectors. PTMs regulate protein activity, localization, and interactions. Variants identified in our patients and in prior studies are highlighted to illustrate their positions within these functionally critical regions.

References

    1. Sugihara, K. , Asano S., Tanaka K., Iwamatsu A., Okawa K., and Ohta Y.. 2002. “The Exocyst Complex Binds the Small GTPase RalA to Mediate Filopodia Formation.” Nature Cell Biology 4, no. 1: 73–78. 10.1038/ncb720 PMID: 11744922. - DOI - PubMed
    1. Ginn, K. F. , Fangman B., Terai K., et al. 2016. “RalA is Overactivated in Medulloblastoma.” Journal of Neuro‐Oncology 130: 99–110. 10.1007/s11060-016-2236-4. - DOI - PubMed
    1. Hiatt, S. M. , Neu M. B., Ramaker R. C., et al. 2018. “De Novo Mutations in the GTP/GDP‐Binding Region of RALA, a RAS‐Like Small GTPase, Cause Intellectual Disability and Developmental Delay.” PLoS Genetics 14: e1007671. 10.1371/journal.pgen.1007671. - DOI - PMC - PubMed
    1. Katsanevaki, D. , Till S. M., Buller‐Peralta I., et al. 2024. “Key Roles of C2/GAP Domains in SYNGAP1‐Related Pathophysiology.” Cell Reports 43: 114733. 10.1016/j.celrep.2024.114733. - DOI - PubMed
    1. Lim, K. H. , Baines A. T., Fiordalisi J. J., et al. 2005. “Activation of RalA is Critical for Ras‐Induced Tumorigenesis of Human Cells.” Cancer Cell 7: 533–545. 10.1016/j.ccr.2005.04.030. - DOI - PubMed

Publication types